International Journal of Cancer最新文献_第2页

Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy. 对于新辅助化疗后肿瘤消退较低的食管胃交界区和胃腺癌患者，辅助FLOT提供了生存优势。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-22 DOI: 10.1002/ijc.70048

Max Kraemer, Naita M Wirsik, Hakan Alakus, Hans A Schloesser, Hans Fuchs, Wolfgang Schroeder, Christiane J Bruns, Su Ir Lyu, Friederike Baehr, Thomas Zander, Alexander Quaas

{"title":"Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy.","authors":"Max Kraemer, Naita M Wirsik, Hakan Alakus, Hans A Schloesser, Hans Fuchs, Wolfgang Schroeder, Christiane J Bruns, Su Ir Lyu, Friederike Baehr, Thomas Zander, Alexander Quaas","doi":"10.1002/ijc.70048","DOIUrl":"https://doi.org/10.1002/ijc.70048","url":null,"abstract":"Oesophagogastric junction and gastric adenocarcinoma (OGA) are associated with high mortality rates, with 5-year survival rates below 50% in the curative setting. This study evaluates the efficacy of adjuvant chemotherapy (a chemotherapy regimen consisting of docetaxel, oxaliplatin, leucovorin and 5-fluorouracil [FLOT]) in patients with low tumour regression grades (TRG) following neoadjuvant FLOT (>10% viable tumour cells in surgical specimen, TRG 2/3 analogue Becker's classification). Data from all patients who had undergone ≥3 cycles of neoadjuvant FLOT with R0 resection and TRG 2/3 in surgical specimen, diagnosed between 2017 and 2020 at the University of Cologne (n = 134), were analyzed. Patients were categorised into three groups based on the administration of postoperative FLOT: 'FLOT complete' (four cycles), 'FLOT incomplete' (one to three cycles) and 'no FLOT' (0 cycles). Progression-free survival (PFS) and overall survival (OS) were compared. There is a statistically significant PFS advantage for the 'FLOT complete' group compared to 'no FLOT' (p = .028) in the total patient cohort and a tendency for an OS benefit. In the subgroup of patients with lymph node metastasis in surgical specimen (ypN+ cohort, n = 91), the PFS advantage of 'FLOT complete' was diminished and statistically no longer significant, and there is no OS benefit for these patients. However, multivariate analysis confirmed a significant PFS benefit for 'FLOT complete' both in the total cohort (p = .011) and in ypN+ patients (p = .018). These findings suggest that full adjuvant FLOT is beneficial even for OGA patients with low tumour regression; however, its efficacy appears reduced in those with lymph node metastasis, warranting further investigation into individualising treatment strategies.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction. 血浆代谢组学分析在肝癌诊断和微血管侵袭预测中的应用。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-22 DOI: 10.1002/ijc.70055

Fei Huang, Huiqin Jiang, Minna Shen, Chunyan Zhang, Yu Chen, Baishen Pan, Beili Wang, Wei Guo, Wenjing Yang

{"title":"Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction.","authors":"Fei Huang, Huiqin Jiang, Minna Shen, Chunyan Zhang, Yu Chen, Baishen Pan, Beili Wang, Wei Guo, Wenjing Yang","doi":"10.1002/ijc.70055","DOIUrl":"https://doi.org/10.1002/ijc.70055","url":null,"abstract":"Altered metabolites are pivotal in hepatocellular carcinoma (HCC) development. This study employed untargeted metabolomic analysis to identify novel biomarkers for early HCC detection and explore their functions. Plasma samples were collected from 138 HCC patients, 69 patients with benign hepatic lesions, and 35 healthy donors. These samples were divided into a discovery set of 171 and a validation set of 71, and analyzed using ultra high performance liquid chromatography mass spectrometry. Through paired t-tests and orthogonal partial least-squares discriminant analysis, nine metabolites with significant predictive value were selected out and incorporated into a model for HCC diagnosis. Area under curves for the discovery set, the validation set, and all samples were 0.97, 0.95, and 0.96, respectively. The satisfactory diagnostic performance was maintained regardless of the China liver cancer (CNLC) staging. Additionally, this model demonstrated better diagnostic performance than alpha-fetoprotein (AFP) when comparing HCC to controls in different CNLC stages. The metabolite pathway enrichment analysis showed that alterations in plasma bile acids were associated with cirrhosis. Univariate and multivariate analyses indicated that the ratio of L-Serine and Sarcosine was an independent predictor for microvascular invasion (MVI). An integrated analysis of metabolomic data with transcriptomic data from the Cancer Genome Atlas revealed that the low expression of alanine glyoxylate aminotransferase (AGXT) and glycine amidinotransferase (GATM) was more likely related to MVI. To sum up, our research findings may offer valuable insights into HCC metabolic alterations and contribute to a better characterization of HCC.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The anti-aging Klotho protects glioblastoma macrophages from radiotherapy-induced inflammation and predicts immunotherapy response. 抗衰老的Klotho保护胶质母细胞瘤巨噬细胞免受放射治疗引起的炎症，并预测免疫治疗反应。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-21 DOI: 10.1002/ijc.70038

Andrea Galluzzo, Martina Maffezzini, Maria Luisa Fumagalli, Irene Sambruni, Silvia Musio, Monica Patanè, Rosina Paterra, Erika Salvi, Manuel Facciolla, Micaela Milani, Marco Schiariti, Luca Mattei, Alessandra Rossi, Marica Eoli, Luigi Poliani, Antonio Silvani, Bianca Pollo, Laura Fariselli, Natalia Di Ianni, Serena Pellegatta

{"title":"The anti-aging Klotho protects glioblastoma macrophages from radiotherapy-induced inflammation and predicts immunotherapy response.","authors":"Andrea Galluzzo, Martina Maffezzini, Maria Luisa Fumagalli, Irene Sambruni, Silvia Musio, Monica Patanè, Rosina Paterra, Erika Salvi, Manuel Facciolla, Micaela Milani, Marco Schiariti, Luca Mattei, Alessandra Rossi, Marica Eoli, Luigi Poliani, Antonio Silvani, Bianca Pollo, Laura Fariselli, Natalia Di Ianni, Serena Pellegatta","doi":"10.1002/ijc.70038","DOIUrl":"https://doi.org/10.1002/ijc.70038","url":null,"abstract":"Immunosuppressive myeloid cells, such as microglia and macrophages, play a key role in mediating resistance to immunotherapy in glioblastoma patients. Bulk RNA sequencing analysis revealed elevated expression of Klotho (Kl) in gliomas derived from irradiated glioma-bearing mice. Klotho, which encodes an anti-aging protein, was found to be upregulated in glioma-associated microglia/macrophages (GAMs) exhibiting an M1 pro-inflammatory phenotype. This upregulation appeared to enhance the antitumor efficacy of a combination of radiotherapy and dendritic cell (DC) immunotherapy. Furthermore, transcript levels of KL in tumor specimens and corresponding serum levels in glioblastoma patients undergoing DC immunotherapy were correlated with favorable prognostic outcomes and improved treatment responses. Given its expression in human M1-like GAMs, serum KL levels can offer valuable insights into the immune microenvironment and hold clinical significance as a peripheral biomarker. These findings highlight the pivotal role of Klotho as a prognostic biomarker for predicting responses to immunotherapy, with potential applications for monitoring tumor progression or regression through changes in serum levels.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plant-based diet index and risk of hepatocellular carcinoma: Findings from a prospective cohort study. 植物性饮食指数与肝细胞癌的风险：一项前瞻性队列研究的结果。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-19 DOI: 10.1002/ijc.70057

Yen Thi-Hai Pham, Renwei Wang, Jaideep Behari, Guo-Chong Chen, Rob M van Dam, Jian-Min Yuan, Hung N Luu

{"title":"Plant-based diet index and risk of hepatocellular carcinoma: Findings from a prospective cohort study.","authors":"Yen Thi-Hai Pham, Renwei Wang, Jaideep Behari, Guo-Chong Chen, Rob M van Dam, Jian-Min Yuan, Hung N Luu","doi":"10.1002/ijc.70057","DOIUrl":"https://doi.org/10.1002/ijc.70057","url":null,"abstract":"The plant-based dietary indices (PDIs), which include the healthy and unhealthy plant-based dietary indices, have recently been developed by taking into account the quantity of plant versus animal foods and the quality of plant foods. Data on the association between PDI and hepatocellular carcinoma (HCC) risk are sparse. We, therefore, prospectively evaluated the associations for PDI, healthy PDI (hPDI) and unhealthy PDI (uPDI) with HCC risk. We used data from the Singapore Chinese Health Study, a prospective cohort study of 63,275 participants aged 45-74 in Singapore who were recruited during the 1993-1998 period. PDI, hPDI, and uPDI were derived from the semi-quantitative food frequency questionnaire at baseline. The incident cases of HCC were identified through record linkage with the Singapore Cancer Registry. Cox proportional hazard regression method was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for HCC in relation to PDI, hPDI, and uPDI. After 17.6 years of follow-up with 819,573 person-years, we identified 561 incident HCC cases. There was an inverse association for HCC risk with PDI (HRper-SD increment = 0.87, 95% CI: 0.79-0.95; Ptrend = 0.009) and hPDI (HRper-SD increment = 0.86, 95% CI: 0.79-0.94; Ptrend = 0.002). This inverse association was similar for HBsAg-negative and HBsAg-positive HCC risk. No association was found between uPDI and HCC risk. In summary, the overall PDI and hPDI were associated with lower risk of HCC in the Chinese Singaporeans. Our findings inform dietary targets for HCC prevention and control programs, particularly in Asian populations.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating ChatGPT's recommendations for systematic treatment decisions in recurrent or metastatic head and neck squamous cell carcinoma: Perspectives from experts and junior doctors. 评估ChatGPT对复发或转移性头颈部鳞状细胞癌系统治疗决策的建议：来自专家和初级医生的观点。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-19 DOI: 10.1002/ijc.70001

Danfang Yan, Lihong Wang, Liming Huang, Kejia Cheng, Yu Huang, Yangyang Bao, Xin Yin, Mengye He, Huiyong Zhu, Senxiang Yan

{"title":"Evaluating ChatGPT's recommendations for systematic treatment decisions in recurrent or metastatic head and neck squamous cell carcinoma: Perspectives from experts and junior doctors.","authors":"Danfang Yan, Lihong Wang, Liming Huang, Kejia Cheng, Yu Huang, Yangyang Bao, Xin Yin, Mengye He, Huiyong Zhu, Senxiang Yan","doi":"10.1002/ijc.70001","DOIUrl":"https://doi.org/10.1002/ijc.70001","url":null,"abstract":"This study evaluates ChatGPT-4's potential as a decision-support tool in the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The study involved 12 retrospectively chosen patients with detailed clinical, tumor, treatment history, imaging, pathology, and symptomatic data. ChatGPT-4, along with six experts and 10 junior oncologists, assessed these cases. The AI model applied the 8th edition AJCC TNM criteria for tumor staging and proposed treatment strategies. Performance was quantitatively rated on a 0-100 scale by both expert and junior oncologists, with further analysis through statistical scoring and intraclass correlation coefficients. Findings revealed that ChatGPT-4 achieved an 83.3% accuracy rate in tumor staging with two instances of mis-staging. Junior doctors rated its staging performance highly, showing strong consensus on language capabilities and moderate on learning assistance. Experts rated ChatGPT-4's treatment strategy: high agreement on subject knowledge (median 86, mean 84.7), logical reasoning (median 83, mean 82), and analytical skills (median 85, mean 82); moderate on ChatGPT-4's usefulness for treatment decision (median 80, mean 77) and its recommendations (median 80, mean 76.8). Junior doctors rated ChatGPT-4 higher in treatment strategy (medians above 85) with limited consensus (subject knowledge: median 88, mean 84.5; logical reasoning: median 90, mean 83.2; analytical skills: median 90, mean 82.5; usefulness: median 85, mean 81.8; agreements for: median 85, mean 80.4). ChatGPT is proficient in tumor staging but moderately effective in treatment recommendations. Nonetheless, it shows promise as a supportive tool for clinicians, particularly for those with less experience, in making informed treatment decisions.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overdiagnosis in low-dose CT lung cancer screening: A systematic review and meta-analysis of overall magnitude and subgroup variations. 低剂量CT肺癌筛查中的过度诊断：总体程度和亚组变化的系统回顾和荟萃分析。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-18 DOI: 10.1002/ijc.70049

Yihui Du, Chengmin Yuan, Xiaoqing Ni, Jingyou Miao, Hui Zhang, Yingming Jiang, Grigory Sidorenkov, Marcel J W Greuter, Geertruida H de Bock, Lilu Ding

{"title":"Overdiagnosis in low-dose CT lung cancer screening: A systematic review and meta-analysis of overall magnitude and subgroup variations.","authors":"Yihui Du, Chengmin Yuan, Xiaoqing Ni, Jingyou Miao, Hui Zhang, Yingming Jiang, Grigory Sidorenkov, Marcel J W Greuter, Geertruida H de Bock, Lilu Ding","doi":"10.1002/ijc.70049","DOIUrl":"https://doi.org/10.1002/ijc.70049","url":null,"abstract":"Overdiagnosis is a major concern in low-dose computed tomography (LDCT) lung cancer screening as it can detect indolent or slow-growing cancers. This study aims to quantify overdiagnosis in LDCT screening and explore its variation by several factors. We conducted a systematic review and meta-analysis following PRISMA guidelines. Four databases (PubMed, Web of Science, Scopus, Cochrane Library) were searched up to October 2024 for studies reporting overdiagnosis in LDCT lung cancer screening. Overdiagnosis was quantified using three metrics: percentage in screen-detected cancers, percentage in all cancers in the screening group, and rate per 1000 screened individuals. Pooled estimates were calculated using random-effects models, and subgroup analyses were performed by follow-up time, histology, nodule type, geography, population risk, and gender. Twenty-six studies were included (8 RCTs, 11 cohorts, 7 ecologic studies). Overdiagnosis declined substantially with extended follow-up, with rates decreasing from 37% (95%CI: 14%-60%) to 7% (95%CI: -7% to 22%; p = .03) for screen-detected cancers and from 25% (95%CI: 8%-41%) to 2% (95%CI: 4%-8%; p = .01) for all screening-group cancers when follow-up exceeded 5 years. This pattern corresponded to overdiagnosis dropping from 12.26 (95%CI: 3.87-20.64) to 1.46 (95%CI: -2.11 to 5.03) per 1000 screened individuals (p = .02). Considerable variations emerged across subgroups: bronchioloalveolar carcinoma 82%, adenocarcinoma 28%, non-adenocarcinoma -11%, p < .001; non-solid cancers 66%, part-solid cancers 31%, solid cancers 7%, p = .002; Asian countries 38%, Western countries 22%, p = .009; general population 38%, high-risk population 22%, p = .010. These findings demonstrate that accurate overdiagnosis assessment requires sufficient follow-up duration and must account for substantial variability across clinical and demographic factors.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144657907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial. 低风险前列腺癌的危险因素：FinRSPC试验中的回顾性队列研究。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-17 DOI: 10.1002/ijc.70026

Uzoamaka E Okwor, Jani Raitanen, Kirsi Talala, Teuvo L J Tammela, Kimmo Taari, Paula Kujala, Anssi Auvinen

{"title":"Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial.","authors":"Uzoamaka E Okwor, Jani Raitanen, Kirsi Talala, Teuvo L J Tammela, Kimmo Taari, Paula Kujala, Anssi Auvinen","doi":"10.1002/ijc.70026","DOIUrl":"https://doi.org/10.1002/ijc.70026","url":null,"abstract":"Overdiagnosis of low-risk prostate cancer (PC), often accompanied by overtreatment, remains an important harmful consequence of prostate-specific antigen (PSA)-based screening. Although PSA screening can reduce PC mortality and metastatic PC, the balance of benefits and harms remains controversial. This retrospective cohort study of 80,144 men from the Finnish Randomized Study of Screening for Prostate Cancer, with a median follow-up of 18.0 years, compared determinants of low-risk PC with determinants of high-risk PC. Low-risk PC (N = 1774) was classified according to the European Association of Urology guidelines, excluding cases with subsequent PC death. A secondary analysis excluded cases with post-diagnosis disease progression. Intermediate, high-risk, and advanced cases were classified as high-risk PC (N = 6466). Poisson regression was used to analyze PC incidence. Low-risk PC was more common in the screening than the control arm (1.9 vs. 1.2 cases per 1000 person-years), whereas high-risk PC was more frequent in the control arm (5.7 vs. 5.4 cases per 1000 person-years in the screening arm). The risk of low-risk PC remained stable across screening rounds, while the risk for high-risk PC declined after the first screen. Age was associated with an increased risk of high-risk PC, but no clear trend by age was observed for low-risk PC. Family history and use of 5-alpha reductase inhibitors showed stronger associations with low-risk PC than high-risk PC, though less so for screen-detected cancers. These suggest that risk factors for low-risk PC differ from those for high-risk PC, with determinants of low-risk PC being more closely related to medical service use.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Socioeconomic background and childhood cancer survival in Germany: A nationwide assessment based on data from the German Childhood Cancer Registry. 德国的社会经济背景和儿童癌症存活率：基于德国儿童癌症登记处数据的全国性评估。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-17 DOI: 10.1002/ijc.70042

Maike Wellbrock, Arndt Borkhardt, Cécile M Ronckers, Claudia Spix, Desiree Grabow, Anna-Liesa Filbert, Daniel Wollschläger, Friederike Erdmann

{"title":"Socioeconomic background and childhood cancer survival in Germany: A nationwide assessment based on data from the German Childhood Cancer Registry.","authors":"Maike Wellbrock, Arndt Borkhardt, Cécile M Ronckers, Claudia Spix, Desiree Grabow, Anna-Liesa Filbert, Daniel Wollschläger, Friederike Erdmann","doi":"10.1002/ijc.70042","DOIUrl":"https://doi.org/10.1002/ijc.70042","url":null,"abstract":"Social inequalities in childhood cancer survival have been observed in many countries, including European nations with universal healthcare systems, suggesting that not all children with cancer have benefited equally from diagnostic and therapeutic enhancements. Despite the growing socioeconomic diversity within Germany's large population, little is known about the extent of social inequalities in German childhood cancer survival. Using German Childhood Cancer Registry data, we identified all children with a cancer diagnosis before the age of 15 years in 1997-2016 in Germany (N = 35,443). Based on individual residential address information (at time of diagnosis) we applied the German Index of Socioeconomic Deprivation (GISD) to measure area-based socioeconomic status. Using Cox proportional hazards models, we assessed the association between absolute area-based socioeconomic deprivation (AASD) and 10-year overall survival (OS) (end of follow-up: 15 January 2023) to estimate hazard ratios (HR) and corresponding 95% confidence intervals (CI). The multivariable analyses revealed a null association for AASD and 10-year OS for all cancers combined (HRadj = 1.00, 95% CI 0.97; 1.03). Among children diagnosed with acute myeloid leukaemia and germ cell tumors, a higher AASD (higher levels of deprivation) appeared to be associated with worse survival, particularly pronounced in boys. The opposite was observed among children diagnosed with central nervous system tumors. Contrary to reports from other European countries, we found little evidence for social inequalities in childhood cancer survival in Germany when analysing the GISD. Further research assessing individual-level measures of socioeconomic status is warranted.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid COJEC without myeloablative therapy for high-risk neuroblastoma. 快速COJEC治疗高危神经母细胞瘤，无需清髓治疗。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-16 DOI: 10.1002/ijc.70043

Brian H Kushner, Ellen M Basu, Fiorella Iglesias Cardenas, Kim Kramer, Shakeel Modak

{"title":"Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.","authors":"Brian H Kushner, Ellen M Basu, Fiorella Iglesias Cardenas, Kim Kramer, Shakeel Modak","doi":"10.1002/ijc.70043","DOIUrl":"https://doi.org/10.1002/ijc.70043","url":null,"abstract":"Myeloablative therapy (MAT) is included in high-risk neuroblastoma (HR-NB) treatment programs of the Children's Oncology Group (COG) and the Societe Internationale d'Oncologie Pediatrique Europe Neuroblastoma (SIOPEN), but not at Memorial Sloan Kettering Cancer Center (MSK). COG and SIOPEN programs achieved 3-5-year event-free survival rates of ~50%-60%, similar to the MSK experience without MAT which involved patients treated with COG or MSK induction and anti-GD2 mAb murine-3F8 + granulocyte-macrophage colony-stimulating factor (GM-CSF). We now present the first report on rapid COJEC without MAT. This retrospective study covers HR-NB patients who received rapid COJEC but not MAT and had no prior progressive disease (PD) when referred to MSK during the era of availability of anti-GD2 mAb naxitamab. The 28 subjects were diagnosed 1/2017-6/2023. Post-COJEC, 10 had no distant disease (Group 1) and 18 had persistence of metastases (Group 2). Group 1 patients had resection of primary tumors and received 1-2 cycles of HR-NB regimens (cyclophosphamide-topotecan ± vincristine), local radiotherapy, and naxitamab + GM-CSF; 9 also received anti-NB vaccine. All 10 remain event-free at median 3.5+ years post-diagnosis. Group 2 patients received second-line therapy post-COJEC, including high-dose cyclophosphamide + topotecan ± vincristine or cyclophosphamide + doxorubicin + vincristine. Treatment after all chemotherapy included naxitamab + GM-CSF ± irinotecan-temozolomide. Thirteen received vaccine. Twelve remain relapse-free at median 2.4+ years post-diagnosis, including 3 who developed secondary neoplasms-myelodysplastic syndrome (n = 2, successfully treated) or thyroid carcinoma. Six developed PD (four are again in complete remission and two died of NB). Avoiding MAT after rapid COJEC does not appear to adversely affect outcome compared to rapid COJEC + MAT.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study. 德国前列腺癌筛查策略的成本效益分析：一项微观模拟研究。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-07-16 DOI: 10.1002/ijc.35513

Muchandifunga Trust Muchadeyi, Shuang Hao, Karla Hernandez-Villafuerte, Shah Alam Khan, Nikolaus Becker, Agne Krilaviciute, Petra Seibold, Roman Gulati, Peter Albers, Michael Schlander, Mark Clements

{"title":"Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.","authors":"Muchandifunga Trust Muchadeyi, Shuang Hao, Karla Hernandez-Villafuerte, Shah Alam Khan, Nikolaus Becker, Agne Krilaviciute, Petra Seibold, Roman Gulati, Peter Albers, Michael Schlander, Mark Clements","doi":"10.1002/ijc.35513","DOIUrl":"10.1002/ijc.35513","url":null,"abstract":"Prostate cancer (PCa) represents a significant public health challenge in Germany, with increasing incidence and economic impact. This study assessed the cost-effectiveness of 10 screening strategies: prostate-specific antigen-based risk-adaptive screening (PSA-RAS), with or without magnetic resonance imaging (MRI), in men starting at age 45 or 50 and stopping at 60 or 70, digital rectal examination (DRE) for ages 45-75 years, and no screening. Using a well calibrated microsimulation model (Swedish Prostata) from a statutory health insurance perspective, lifetime outcomes were evaluated, including cancer incidence, mortality, overdiagnosis, biopsies, life-years, and quality-adjusted life-years (QALYs) discounted annually at 3%. Cost and utility inputs were derived from the German diagnostic-related group schedule, fee-for-service catalogues, literature, and expert opinion. DRE-only was the least cost-effective, yielding high biopsy and overdiagnosis rates with minimal QALY gains. PSA-RAS reduced overdiagnosis and biopsy rates, with PSA-RAS (50-60 years) without MRI emerging as the most cost-efficient strategy, saving approximately €1.2 million per 100,000 men compared with no screening. Extending the PSA-RAS to 70 years improved its effectiveness in terms of QALYs. PSA-RAS (50-70) with MRI could become cost-effective at an increasing willingness to pay threshold or decreasing MRI cost. This study suggests the potential of PSA-RAS to improve PCa screening in Germany. Incorporating MRI, reducing MRI cost within the screening setting, and extending screening to 70 to align with EU recommendations could improve the cost-effectiveness of PSA-RAS with MRI. Future research should explore the integration of MRI with ancillary tests, such as 4K-score or risk calculators, to reduce MRI use and associated costs.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0